Microfluidic Nitric Oxide Sensor
微流控一氧化氮传感器
基本信息
- 批准号:9347968
- 负责人:
- 金额:$ 72.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAuthorization documentationBacterial InfectionsBenchmarkingBiochemical MarkersBiological MarkersBloodCalibrationCaringCause of DeathCessation of lifeChemicalsClinicClinicalClinical MarkersClinical ResearchComplexCritical IllnessCritical PathwaysDetectionDevicesDiagnosisDiagnosticDiseaseEngineeringEnsureFunctional disorderGenerationsHealth Care CostsImmune responseIn SituIn VitroIncidenceInfectionIntensive Care UnitsInvestigationLaboratory MarkersMeasurementMeasuresMethodsMicrofluidicsMonitorMorbidity - disease rateNitric OxideOrganPathologicPatient CarePatientsPerformancePhasePopulationPositioning AttributePre-Clinical ModelPreparationProductionProtocols documentationQualifyingResearchResearch PersonnelRouteSamplingScientistSepsisSiteSmall Business Technology Transfer ResearchSyndromeSystemSystemic infectionTechniquesTestingWhole Bloodbaseclinical Diagnosiscostimaging biomarkerimprovedmanufacturing processmortalitypathogenpatient populationphase 2 studypotential biomarkerprototyperesponsesensorsepticsuccesstool
项目摘要
PROJECT SUMMARY
Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in
whole blood. This STTR Phase II project aims to complete several key aims necessary to commercialize this
device, including a clinical study where NO levels will be evaluated clinically in sepsis. Sepsis is the leading
cause of death in non-cardiac intensive care units (ICUs). Each year, sepsis affects 1.6 million people, causing
250,000 deaths and healthcare costs over $20 billion. The incidence and cost burden of sepsis are steadily
increasing. Broadly defined, sepsis has been understood as a pathophysiological state in response to systemic
infection by bacterial and/or fungal pathogens in blood. The definition of sepsis is continually evolving as new
research emerges about this disease and clinicians seek to better manage patient care. However, the treatment
paradigm remains consistent: prompt detection and action are critical for reducing sepsis-associated morbidity
and mortality and reducing the costs associated with sepsis care. Currently, sepsis and its associated
syndromes “lack specific clinical, imaging, laboratory, or biochemical markers with which to confirm their
presence.” Nitric oxide (NO) is endogenously produced in the host response to infection, is a causative agent
in sepsis-induced organ dysfunction, and has been proposed as a potential biomarker for sepsis. Until recently,
no tools have existed to measure NO directly in complex matrices such as blood. We have developed a first-in-
class microfluidic sensor that enables measurement of NO in whole blood. With this tool, we have
demonstrated that NO levels increase rapidly in preclinical models of sepsis. In Phase I, we developed a
prototype sensor, demonstrated its unprecedented analytical performance in blood, and confirmed its ability
to monitor pathophysiologic NO levels in a pre-clinical model. For Phase II, we have assembled a team of
scientists, engineers, and clinical researchers to complete key steps on the critical path to receiving an
Investigational Device Exemption (IDE) and ultimately commercialize this device.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bruce A Cairns其他文献
Bruce A Cairns的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bruce A Cairns', 18)}}的其他基金
Multi-modal rescue of pulmonary NRF2-insufficiency after burn and burn + inhalation injury to regulate innate immune dysfunction
烧伤及烧伤吸入性损伤后肺NRF2不足的多模式抢救调节先天免疫功能障碍
- 批准号:
10435748 - 财政年份:2022
- 资助金额:
$ 72.37万 - 项目类别:
Multi-modal rescue of pulmonary NRF2-insufficiency after burn and burn + inhalation injury to regulate innate immune dysfunction
烧伤及烧伤吸入性损伤后肺NRF2不足的多模式抢救调节先天免疫功能障碍
- 批准号:
10732822 - 财政年份:2022
- 资助金额:
$ 72.37万 - 项目类别:
Multi-modal rescue of pulmonary NRF2-insufficiency after burn and burn + inhalation injury to regulate innate immune dysfunction
烧伤及烧伤吸入性损伤后肺NRF2不足的多模式抢救调节先天免疫功能障碍
- 批准号:
10651857 - 财政年份:2022
- 资助金额:
$ 72.37万 - 项目类别:
Damage-Induced Activation of the TLR/mTOR/PPARg Axis Regulates the Immune Response After Burn and Inhalation Injury
损伤诱导的 TLR/mTOR/PPARg 轴激活调节烧伤和吸入性损伤后的免疫反应
- 批准号:
10300052 - 财政年份:2018
- 资助金额:
$ 72.37万 - 项目类别:
Damage-Induced Activation of the TLR/mTOR/PPARg Axis Regulates the Immune Response After Burn and Inhalation Injury
损伤诱导的 TLR/mTOR/PPARg 轴激活调节烧伤和吸入性损伤后的免疫反应
- 批准号:
10062997 - 财政年份:2018
- 资助金额:
$ 72.37万 - 项目类别:
Damage-Induced Activation of the TLR/mTOR/PPARg Axis Regulates the Immune Response After Burn and Inhalation Injury
损伤诱导的 TLR/mTOR/PPARg 轴激活调节烧伤和吸入性损伤后的免疫反应
- 批准号:
10531808 - 财政年份:2018
- 资助金额:
$ 72.37万 - 项目类别:
Role of extraceullar vesicles in directing immunometabolic homeostasis after burn injury
细胞外囊泡在烧伤后指导免疫代谢稳态中的作用
- 批准号:
10337838 - 财政年份:2018
- 资助金额:
$ 72.37万 - 项目类别:
Cellular mechanism of immune dysfunction following burn injury
烧伤后免疫功能障碍的细胞机制
- 批准号:
8445370 - 财政年份:2009
- 资助金额:
$ 72.37万 - 项目类别:
Cellular mechanism of immune dysfunction following burn injury
烧伤后免疫功能障碍的细胞机制
- 批准号:
7799750 - 财政年份:2009
- 资助金额:
$ 72.37万 - 项目类别:
Cellular mechanism of immune dysfunction following burn injury
烧伤后免疫功能障碍的细胞机制
- 批准号:
8244359 - 财政年份:2009
- 资助金额:
$ 72.37万 - 项目类别:
相似海外基金
OncoPath: Intelligent Clinical Pathway Decision Support Tool for Pre-Authorization Documentation in Non-Small Cell Lung Cancer Treatment
OncoPath:用于非小细胞肺癌治疗预授权文档的智能临床路径决策支持工具
- 批准号:
10325551 - 财政年份:2021
- 资助金额:
$ 72.37万 - 项目类别: